Block Deal: Pharma stock jumps 8% after 13 Lakh shares change hands

Synopsis: Bliss GVS Pharma shares surged 8% following a block deal of 13.26 lakh shares (1.26% equity) valued at Rs. 25.4 crore, signalling notable institutional trading activity. The stock has risen 17% in the past month.

This company is engaged in manufacturing, marketing, trading, and exporting of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups, is now in the spotlight after 1.26% worth of equity changed hands.

With a market capitalisation of Rs. 1,997 cr, the shares of Bliss GVS Pharma Ltd are currently trading at Rs. 188.80 per share, jumping 8% in today’s market session, making a high of Rs. 195.85, up from its previous close of Rs. 181.30 per share. The stock posted a 7% return over the past year, with year-to-date and the last six months’ gains both at 16%, and a 17% increase in the past month.

Block Deal

Bliss GVS Pharma witnessed a significant block trade on the stock market. A total of 13.26 lakh shares, representing 1.26% of the company’s equity, were traded through a block deal. 

The shares changed hands at an average price of Rs. 192 per share, valuing the transaction at approximately Rs. 25.4 crore. Block deals like this usually involve large investors or institutions and can indicate portfolio adjustments or strategic stake transfers. 

Company Profile

Bliss GVS is a rapidly growing pharmaceutical company with over three decades of industry experience. It develops, manufactures, and markets high-quality, affordable pharmaceutical formulations for the global market. The company is a world leader in Suppositories and Pessaries.

It demonstrates healthy financial performance with a Return on Capital Employed (ROCE) of 11.7% and a Return on Equity (ROE) of 8.36%, indicating efficient utilisation of capital and shareholder funds. The company’s debt-to-equity ratio is low at 0.05, reflecting a strong balance sheet and reduced reliance on debt.

The stock appears reasonably valued with a Price-to-Earnings (P/E) ratio of 18.3, below the industry average of 30.7, and a PEG ratio of 0.42, suggesting potential for growth relative to earnings. 

Sales of the company increased from Rs. 207 cr in Q1FY26 to Rs. 244 cr in Q2FY26. Operating profit declined to Rs. 32 cr from Rs. 41 cr. Net profit also fell from Rs. 44 cr to Rs. 29 cr over the same period.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Block Deal: Pharma stock jumps 8% after 13 Lakh shares change hands appeared first on Trade Brains.